249 related articles for article (PubMed ID: 36389657)
1. Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review.
Milosevic E; Babic A; Iovino L; Markovic M; Grce M; Greinix H
Front Immunol; 2022; 13():1033263. PubMed ID: 36389657
[TBL] [Abstract][Full Text] [Related]
2. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
Front Immunol; 2019; 10():1879. PubMed ID: 31507582
[TBL] [Abstract][Full Text] [Related]
3. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
4. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.
Kuzmina Z; Krenn K; Petkov V; Körmöczi U; Weigl R; Rottal A; Kalhs P; Mitterbauer M; Ponhold L; Dekan G; Greinix HT; Pickl WF
Blood; 2013 Mar; 121(10):1886-95. PubMed ID: 23303823
[TBL] [Abstract][Full Text] [Related]
5. Value of Autoantibody Expression During Long-Term Follow-Up in Paediatric ALL Patients After Allogeneic Haematopoietic Stem Cell Transplantation.
Lawitschka A; Ronceray L; Bauer D; Rittenschober M; Zubarovskaya N; Geyeregger R; Pickl WF; Kuzmina Z
Front Pediatr; 2021; 9():788360. PubMed ID: 34993166
[No Abstract] [Full Text] [Related]
6. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.
Kariminia A; Holtan SG; Ivison S; Rozmus J; Hebert MJ; Martin PJ; Lee SJ; Wolff D; Subrt P; Abdossamadi S; Sung S; Storek J; Levings M; Aljurf M; Arora M; Cutler C; Gallagher G; Kuruvilla J; Lipton J; Nevill TJ; Newell LF; Panzarella T; Pidala J; Popradi G; Szwajcer D; Tay J; Toze CL; Walker I; Couban S; Storer BE; Schultz KR
Blood; 2016 Jun; 127(24):3082-91. PubMed ID: 27020088
[TBL] [Abstract][Full Text] [Related]
8. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
9. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
[TBL] [Abstract][Full Text] [Related]
11. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.
Greinix HT; Kuzmina Z; Weigl R; Körmoczi U; Rottal A; Wolff D; Kralj M; Kalhs P; Mitterbauer M; Rabitsch W; Edinger M; Holler E; Pickl WF
Biol Blood Marrow Transplant; 2015 Feb; 21(2):250-8. PubMed ID: 25460358
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria.
Pengpis N; Prueksrisakul T; Chanswangphuwana C
Med Oral Patol Oral Cir Bucal; 2023 Mar; 28(2):e167-e173. PubMed ID: 36173715
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis.
Rozmus J; Kariminia A; Abdossamadi S; Storer BE; Martin PJ; Lee SJ; Wolff D; Arora M; Cutler C; Schultz KR
Biol Blood Marrow Transplant; 2019 Mar; 25(3):451-458. PubMed ID: 30447393
[TBL] [Abstract][Full Text] [Related]
15. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.
Schultz KR; Kariminia A; Ng B; Abdossamadi S; Lauener M; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savasan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Azadpour S; Ostroumov E; Subrt P; Halevy A; Mostafavi S; Cuvelier GDE
Blood; 2020 Apr; 135(15):1287-1298. PubMed ID: 32047896
[TBL] [Abstract][Full Text] [Related]
16. Consensus recommendations for improvement of unmet clinical needs--the example of chronic graft-versus-host disease: a systematic review and meta-analysis.
Olivieri J; Manfredi L; Postacchini L; Tedesco S; Leoni P; Gabrielli A; Rambaldi A; Bacigalupo A; Olivieri A; Pomponio G
Lancet Haematol; 2015 Jul; 2(7):e297-305. PubMed ID: 26688385
[TBL] [Abstract][Full Text] [Related]
17. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
[TBL] [Abstract][Full Text] [Related]
18. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.
Cuvelier GDE; Ng B; Abdossamadi S; Nemecek ER; Melton A; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Ostroumov E; Schultz KR
Blood Adv; 2023 Jul; 7(14):3612-3623. PubMed ID: 36219586
[TBL] [Abstract][Full Text] [Related]
19. Biomarker Panel for Chronic Graft-Versus-Host Disease.
Yu J; Storer BE; Kushekhar K; Abu Zaid M; Zhang Q; Gafken PR; Ogata Y; Martin PJ; Flowers ME; Hansen JA; Arora M; Cutler C; Jagasia M; Pidala J; Hamilton BK; Chen GL; Pusic I; Lee SJ; Paczesny S
J Clin Oncol; 2016 Aug; 34(22):2583-90. PubMed ID: 27217465
[TBL] [Abstract][Full Text] [Related]
20. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
Mitchell SA; Jacobsohn D; Thormann Powers KE; Carpenter PA; Flowers ME; Cowen EW; Schubert M; Turner ML; Lee SJ; Martin P; Bishop MR; Baird K; Bolaños-Meade J; Boyd K; Fall-Dickson JM; Gerber LH; Guadagnini JP; Imanguli M; Krumlauf MC; Lawley L; Li L; Reeve BB; Clayton JA; Vogelsang GB; Pavletic SZ
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1619-29. PubMed ID: 21536143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
